TL;DR
To increase the proportion of patients who achieve durable TFR, future efforts should focus on the development of risk-adapted consolidation strategies incorporating optimized TKI therapy, immune modulation, and LSC-targeted approaches.
These observations argue against reliance on any single biomarker and instead support integrated models incorporating clinical variables, molecular residual disease, immune competence, immunogenetics, and LSC biology that may enable a transition from empiric TKI discontinuation toward precision, biomarker‐guided TFR an...
The pivotal role of LSCs in disease progression and relapse is highlighted, potential molecular and epigenetic regulators as new targets for intervention are evaluated, and the development of combination treatment strategies to improve TFR rates and move towards curative outcomes is supported.
Chronic myeloid leukemia (CML) therapy has evolved from survival-oriented management into the pursuit of a “functional cure,” characterized by treatment-free remission (TFR). Achieving a deep molecular response (DMR) is a critical prerequisite for TFR and recent clinical advances have introduced novel therapeutic optio...
Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) into a chronic condition with near-normal life expectancy. As patients remain on therapy for years, health-related quality of life (HRQoL) and patient-reported outcomes (PROs) are increasingly important in therapeutic decision-making. H...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
